Close Menu
Technology Mag

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    The influencer in this Vodafone ad isn’t real

    September 8, 2025

    Google finally details Gemini usage limits

    September 7, 2025

    GM slows EV production as tax credit nears expiration

    September 7, 2025
    Facebook X (Twitter) Instagram
    Subscribe
    Technology Mag
    Facebook X (Twitter) Instagram YouTube
    • Home
    • News
    • Business
    • Games
    • Gear
    • Reviews
    • Science
    • Security
    • Trending
    • Press Release
    Technology Mag
    Home » The Gut Might Hold the Key to Treating Long Covid in Kids
    Science

    The Gut Might Hold the Key to Treating Long Covid in Kids

    News RoomBy News RoomOctober 1, 20243 Mins Read
    Facebook Twitter Pinterest LinkedIn Reddit WhatsApp Email

    Yonker and her colleagues will administer larazotide to 32 patients between the ages of 7 and 21, who will take the drug for eight weeks; a further 16 patients will receive a placebo. To qualify for the trial, patients must have a detectable presence of the Covid-19 spike protein in their blood. The intention is to see whether reducing intestinal permeability can make a noticeable difference to the young patients’ symptoms and quality of life.

    Running such a trial has not been straightforward. “It began last year, but we had to put it on pause for a few months because of staffing and drug supply issues,” says Yonker. “One of the requirements is that we need to ensure that the spike protein is present in the blood, which can involve multiple blood draws from these children, which takes time. Because of this I expect it will take one to two more years to recruit all the patients we need, but I would love to move faster.”

    The results, when they emerge, will help researchers determine whether a leaky gut is likely to be a major cause of disease in at least a subset of patients, and whether larazotide should be trialed more widely as a possible treatment.

    There could be other gut-related involvement: Brodin believes that in some children, the virus lingers in the gut rather than being fully excreted, enabling it to actively damage the intestinal wall and contributing to gastrointestinal problems. He suspects that this viral persistence can then induce an autoimmune reaction in the bloodstream, causing further symptoms.

    Yonker’s trial is also encouraging other pediatric long Covid researchers to initiate their own trials, exploring other theories behind the condition. Danilo Buonsenso, a pediatrician at the Gemelli University Hospital in Rome who conducted the first study examining whether children were developing long Covid, described the study as fascinating. He is now trying to get funding for an ambitious trial testing multiple treatments.

    Buonsenso’s work includes studies suggesting that blood clots, as well as inflammation within the lining of the blood vessels known as the endothelium, may play a role in driving certain symptoms. Separately, he led a study that found some children with long Covid also struggle with a condition called postural tachycardia syndrome (POTS) that affects many adults with long Covid, too.

    “In my opinion, there will not be a single drug that will solve long Covid, as multiple things are being documented,” he says. “We need to investigate the role of low-dose anticoagulants with known effects on reducing endothelial inflammation. But we also need to look at specific drugs for POTS and specific medications for the neurocognitive symptoms like chronic pain and headache.”

    Meanwhile, Yonker’s focus on the gut represents a crucial first step. Given the desperation of children suffering from the condition, and their parents, she is hopeful that if her trial proves successful, it will provide an evidence-based treatment option specifically for children. “I think it’s extremely important to advocate for timely treatment advances in children suffering from long Covid rather than wait for trickle-down guidance, based on what we see from trials in adults,” she says.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email
    Previous ArticleNintendo has reportedly shut down Ryujinx, the Switch emulator that was supposedly immune
    Next Article Snap employees were well aware of the app’s child safety issues, newly unsealed complaint says

    Related Posts

    China Is Building a Brain-Computer Interface Industry

    September 7, 2025

    Hungry Worms Could Help Solve Plastic Pollution

    September 6, 2025

    Extreme Heat Makes Your Body Age Faster

    September 5, 2025

    Arkansas Hosts the Planet’s Only Public Diamond Mine

    September 4, 2025

    What Is the Magnetic Constant, and Why Does It Matter?

    September 4, 2025

    Top CDC Officials Resign After Director Is Pushed Out

    September 4, 2025
    Our Picks

    Google finally details Gemini usage limits

    September 7, 2025

    GM slows EV production as tax credit nears expiration

    September 7, 2025

    Computer chips, with a side of forever chemicals

    September 7, 2025

    A really cheap way to get really smart lights

    September 7, 2025
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss
    Science

    China Is Building a Brain-Computer Interface Industry

    By News RoomSeptember 7, 2025

    Given these and other recent milestones, Peng says it’s realistic to think that at least…

    The Doomers Who Insist AI Will Kill Us All

    September 7, 2025

    Pocket Scion is a synth you play with plants

    September 6, 2025

    Bluetti says it can reduce vanlife power installations to ‘30 minutes’

    September 6, 2025
    Facebook X (Twitter) Instagram Pinterest
    • Privacy Policy
    • Terms of use
    • Advertise
    • Contact
    © 2025 Technology Mag. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.